Compass Therapeutics, Inc.
CMPX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001738021
In the last 90 days, Compass Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 215 institutions reported holding it in 13F filings for Q2 2026, worth $363.4M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Compass Therapeutics, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 173 | 3 | 201 | +31 |
| Shares | 164.1M | 8.06M | 173.7M | +17.6M (+11.3%) |
| Value | $881.5M | $43.3M | $921.3M | +$83.2M (+9.9%) |
3 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (50)
Institutions that held Compass Therapeutics, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
Sold out (19)
Institutions that held Compass Therapeutics, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Trails Edge Capital Partners, LP | 1,415,273 | $7.60M |
| Marshall Wace, LLP | 1,263,647 | $6.79M |
| HighVista Strategies LLC | 245,532 | $1.32M |
| Arrowstreet Capital, Limited Partnership | 210,249 | $1.13M |
| Boothbay Fund Management, LLC | 205,024 | $1.10M |
| Gsa Capital Partners LLP | 133,810 | $719.0K |
| NEOS Investment Management LLC | 101,676 | $546.0K |
| CM Management, LLC | 100,000 | $537.0K |
| SummitTX Capital, L.P. | 81,449 | $437.4K |
| Jane Street Group, LLC | 70,063 | $376.2K |
| Caxton Corp | 29,495 | $158.4K |
| Avanza Fonder AB | 27,347 | $146.9K |
| Two Sigma Advisers, LP | 15,200 | $81.6K |
| Flagship Harbor Advisors, LLC | 6,000 | $32.2K |
| Acadian Asset Management LLC | 4,867 | $26.0K |
| Amalgamated Bank | 4,111 | $22.0K |
| Cape Investment Advisory, Inc. | 2,002 | $10.8K |
| Bessemer Group Inc | 526 | $3.00K |
| SRS Capital Advisors, Inc. | 18 | $97 |
Not filed for Q1 2026 yet (3)
Institutions that held Compass Therapeutics, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 8,048,374 | $43.2M |
| Financial Advisory Corp | 13,495 | $72.0K |
| CIBC Private Wealth Group, LLC | 38 | $204 |